XERS Xeris Pharmaceuticals Inc.

10.4
0  0%
Previous Close 10.4
Open
Price To Book 2.61
Market Cap 280,178,382
Shares 26,940,229
Volume 0
Short Ratio
Av. Daily Volume 190,346

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 2H 2019.
Continuous glucagon
Hypoglycemia-Associated Autonomic Failure
Phase 3 trial to be initiated mid-2019.
Continuous glucagon
Congenital Hyperinsulinism
Phase 2 data due 2H 2019.
Self administered glucagon
Exercise-Induced Hypoglycemia
Phase 2b data due 2H 2019.
Self administered glucagon
Post-Bariatric Hypoglycemia
PDUFA date extended by three months to September 10, 2019.
Glucagon Rescue Pen
Severe hypoglycemia
Phase 2 trial to be initiated 2H 2019.
Diazepam
Seizures

Latest News

  1. Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon
  2. Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register?
  3. Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline
  4. Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam
  5. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  6. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  7. Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
  8. Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
  9. How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?
  10. Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
  11. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  12. Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
  13. Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
  14. Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today
  15. The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
  16. Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock
  17. European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)
  18. Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress
  19. Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen
  20. Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon